FNY Managed Accounts’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

FNY Managed Accounts’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,500	Closed	-$26K	–	976
2017 Q4	$26K	Buy	+1,500	New	+$18.5K	0.02%	122
2015 Q4	–	Sell	-1,500	Closed	-$29.8K	–	461
2015 Q3	$29.8K	Buy	+1,500	New	+$34.4K	0.08%	189
2015 Q2	–	Sell	-800	Closed	-$12.4K	–	644
2015 Q1	$12.4K	Buy	+800	New	+$12.4K	0.01%	227

Other funds holding SCMP

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AIM

Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

FNY Managed Accounts's SCMP Position: Q1 2018 in Review

FNY Managed Accounts sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 1,500 shares — an estimated $26K sold.

FNY Managed Accounts first reported a position in SCMP in Q1 2015 and held it in 3 quarters. The position peaked at $29.8K in Q3 2015. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

FNY Managed Accounts reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
FNY Managed Accounts sold 1,500 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $26K.
FNY Managed Accounts first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2015 and held it in 3 quarters.
FNY Managed Accounts's Sucampo Pharmaceuticals, Inc. position peaked at $29.8K in Q3 2015.
3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.